Skip to content

CHRS - Coherus Oncology, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchC

Coherus BioSciences Inc

CHRS · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

C

CHRSCoherus BioSciences Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $2.62
52-wk low: $1.09
Prev close: $1.91
Mkt cap: $205.5M
Fwd P/E: 41.1x
Beta: 0.95

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$26.9M

TS
Two Sigma
Q2 2026 13F
$3.2M
position
AQ
AQR
Q2 2026 13F

Earnings

Reported Aug 5, 2026

Earnings came in 37.5% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -259.4%
Forward P/E: 41.15
Market cap: $205M

Valuation

P/S4.03
P/B3.40

Quality

Operating margin-226.0%

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: CHRS
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $205.49M
Beta: 0.95

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/S

4.0x

P/B

3.4x

Profit margin

-259.4%

Op margin

-226.0%

ROE

-178.4%

$1.9M

position

JS

Jim Simons

Q2 2026 13F

$788K

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for CHRS

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.22-37.5%

-$0.16 expected

Next report

What the street expects next

ROE

-178.4%

ROA-30.5%

Growth

Beta0.95